| A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors (NCT01724320) | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2012-02-01 |
| A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma (NCT01537744) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2012-02-01 |
| A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056) (NCT01431534) | Merck Sharp & Dohme LLC | 2012-01-30 |
| A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies (NCT01470209) | Emory University | 2012-01-01 |
| A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors (NCT01457417) | Leap Therapeutics, Inc. | 2012-01-01 |
| HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors (NCT01509300) | Asan Medical Center | 2012-01-01 |
| Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors (NCT01496534) | Matthew Galsky | 2012-01-01 |
| BKM120 in Cancers With PIK3CA Activating Mutations (NCT01501604) | Massachusetts General Hospital | 2012-01-01 |
| Clinical Trial of ARQ 761 in Advanced Solid Tumors (NCT01502800) | University of Texas Southwestern Medical Center | 2011-12-29 |
| Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650) (NCT01463696) | Merck Sharp & Dohme LLC | 2011-12-21 |
| Dose Escalation Study of Pazopanib Plus TH-302 (NCT01485042) | Herbert Hurwitz, MD | 2011-12-01 |
| Phase I Study of CS-7017 and Bexarotene (NCT01504490) | Georgetown University | 2011-12-01 |
| Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects (NCT01517399) | Daiichi Sankyo | 2011-12-01 |
| Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function (NCT01443481) | Novartis Pharmaceuticals | 2011-11-01 |
| A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors (NCT02496949) | Chinese Academy of Medical Sciences | 2011-11-01 |
| The Effects of Ginseng on Cancer-Related Fatigue (NCT01375114) | M.D. Anderson Cancer Center | 2011-10-14 |
| Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients (NCT01430572) | M.D. Anderson Cancer Center | 2011-10-07 |
| Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma (NCT01438554) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2011-10-01 |
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies (NCT01461538) | Seagen Inc. | 2011-10-01 |
| Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors (NCT01447225) | Merrimack Pharmaceuticals | 2011-10-01 |
| Nivestim® (Filgrastim) Tolerance in Patients Treated by Toxic Chemotherapeutic Agents (NCT01574235) | Hospira, now a wholly owned subsidiary of Pfizer | 2011-10-01 |
| Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia (NCT01444456) | Amgen | 2011-10-01 |
| Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer (NCT01497925) | Polaris Group | 2011-09-06 |
| Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure. (NCT01878890) | Institut Bergonié | 2011-09-05 |
| Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors (NCT01401868) | MEI Pharma, Inc. | 2011-09-01 |
| CPCT-02 Biopsy Protocol (NCT01855477) | Foundation CPCT | 2011-08-17 |
| TrasGEX™: Phase 1 Study in Cancer Patients (NCT01409343) | Glycotope GmbH | 2011-07-01 |
| Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors (NCT01379287) | Memorial Sloan Kettering Cancer Center | 2011-06-20 |
| A Study Of PF-04449913 Administered Alone In Select Solid Tumors (NCT01286467) | Pfizer | 2011-05-11 |
| Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors (NCT01311713) | Teva Branded Pharmaceutical Products R&D, Inc. | 2011-05-02 |
| A Study of LY2523355 in Patients With Solid Cancer (NCT01358019) | Kyowa Kirin Co., Ltd. | 2011-05-01 |
| Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors (NCT01357330) | Sanofi | 2011-05-01 |
| A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors (NCT01345201) | OncoMed Pharmaceuticals, Inc. | 2011-05-01 |
| PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment (NCT01581541) | National Cancer Institute (NCI) | 2011-04-26 |
| QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas (NCT01231347) | NantCell, Inc. | 2011-04-07 |
| A Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy (NCT01159522) | SynCore Biotechnology Co., Ltd. | 2011-04-01 |
| A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors (NCT01240655) | Novartis Pharmaceuticals | 2011-04-01 |
| Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors (NCT01336842) | University of California, Davis | 2011-04-01 |
| Target Therapies Resistance Molecular Profiling in Patients With Neoplastic Disease (NCT03347318) | Fondazione del Piemonte per l'Oncologia | 2011-03-30 |
| A Study of DS-2248 in Participants With Advanced Solid Tumors (NCT01288430) | Daiichi Sankyo | 2011-03-29 |
| Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (NCT01327612) | Amgen | 2011-03-03 |
| GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid Tumors (NCT01313598) | Lakefront Biotherapeutics NV | 2011-03-01 |
| Feasibility Clinical Study of Targeted and Genome-Wide Sequencing (NCT01345513) | University Health Network, Toronto | 2011-03-01 |
| BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors (NCT01297452) | Memorial Sloan Kettering Cancer Center | 2011-02-15 |
| Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors (NCT01294670) | Memorial Sloan Kettering Cancer Center | 2011-02-09 |
| Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer (NCT01553656) | Exelixis | 2011-02-01 |
| A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer (NCT01300533) | BIND Therapeutics | 2011-01-01 |
| Study of PM060184 in Patients With Advanced Solid Tumors (NCT01299636) | PharmaMar | 2011-01-01 |
| Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors (NCT01313065) | Vaccinex Inc. | 2011-01-01 |
| Safety Study of Sterile Compound C31510 for Injection to Subjects With Solid Tumors (NCT01251562) | BPGbio | 2011-01-01 |
| Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas (NCT01279603) | Genus Oncology, LLC | 2011-01-01 |
| Study of Nesvacumab (REGN910/ SAR307746) (NCT01271972) | Regeneron Pharmaceuticals | 2011-01-01 |
| High Dose Chemotherapy With Amifostine and Autologous Stem Cell Transplantation for High Risk Relapsed Pediatric Solid Tumors and Brain Tumors (NCT05167370) | Children's Hospital Medical Center, Cincinnati | 2010-12-13 |
| Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors (NCT01259479) | National Cancer Institute (NCI) | 2010-12-03 |
| A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors (NCT01277146) | OncoMed Pharmaceuticals, Inc. | 2010-12-01 |
| AT13387 in Adults With Refractory Solid Tumors (NCT01246102) | National Cancer Institute (NCI) | 2010-11-19 |
| A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005) (NCT01226901) | Merck Sharp & Dohme LLC | 2010-11-01 |
| Mesenchymal Stem Cells In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ Cancers (NCT01275612) | Mario Negri Institute for Pharmacological Research | 2010-11-01 |
| Safety Study of MG1102 in Patients With Solid Tumors (NCT01809912) | Green Cross Corporation | 2010-11-01 |
| Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors (NCT01245543) | Daiichi Sankyo | 2010-11-01 |
| Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance (NCT01197170) | M.D. Anderson Cancer Center | 2010-09-07 |
| Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer (NCT01197885) | Ganymed Pharmaceuticals GmbH | 2010-09-03 |
| Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor (NCT01212341) | Seoul National University Hospital | 2010-09-01 |
| Study of CH5132799 Administered Orally in Patients With Advanced Solid Tumors (NCT01222546) | Chugai Pharma Europe Ltd. | 2010-08-01 |
| CetuGEX™: Phase 1 Study in Cancer Patients (NCT01222637) | Glycotope GmbH | 2010-08-01 |
| Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment (NCT01158079) | Alnylam Pharmaceuticals | 2010-07-01 |
| Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors (NCT01283945) | Institut de Recherches Internationales Servier | 2010-07-01 |
| Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors (NCT01149720) | Daiichi Sankyo | 2010-07-01 |
| Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors (NCT01949688) | Shiga University | 2010-06-01 |
| To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors (NCT01199224) | AbbVie | 2010-06-01 |
| Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules (NCT01170975) | Genta Incorporated | 2010-06-01 |
| Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors (NCT01165385) | UNICANCER | 2010-06-01 |
| Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors (NCT01190644) | Merck Sharp & Dohme LLC | 2010-06-01 |
| A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax (NCT01121133) | AbbVie | 2010-05-01 |
| A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869) (NCT01114191) | Abbott | 2010-05-01 |
| First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors (NCT01110083) | EMD Serono | 2010-04-01 |
| Study of Vinblastine and Sirolimus in Children With Recurrent/Refractory Solid Tumours Including CNS Tumours (NCT01135563) | The Hospital for Sick Children | 2010-04-01 |
| Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors (NCT01129349) | Amgen | 2010-04-01 |
| Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas (NCT01078649) | Debiopharm International SA | 2010-03-29 |
| Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors (NCT01127178) | Eisai Inc. | 2010-03-29 |
| A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007) (NCT01071018) | Merck Sharp & Dohme LLC | 2010-02-01 |
| Study of EZN-2208 Pediatric Patients With Solid Tumors (NCT01295697) | Enzon Pharmaceuticals, Inc. | 2010-02-01 |
| Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors (NCT01072890) | University of California, Davis | 2010-02-01 |
| Evaluation of Thymidine Kinase Activity in the Serum of Patients With Solid Tumors (NCT01050413) | Hadassah Medical Organization | 2010-02-01 |
| A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II) (NCT01100931) | National Cancer Institute (NCI) | 2010-02-01 |
| Caris Molecular Intelligence Registry (NCT02678754) | Caris Science, Inc. | 2010-02-01 |
| A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005 (NCT01047007) | Merck Sharp & Dohme LLC | 2010-01-18 |
| A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax). (NCT01021358) | Abbott | 2010-01-01 |
| Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors (NCT01049893) | Daiichi Sankyo | 2010-01-01 |
| Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010) (NCT01002924) | Endocyte | 2009-12-31 |
| Feasibility Study for Imaging of Peripheral Tumors With a High-Resolution PET Imaging System (NCT01008930) | M.D. Anderson Cancer Center | 2009-12-01 |
| A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) (NCT00960063) | Merck Sharp & Dohme LLC | 2009-11-11 |
| PankoMab-GEX™: Phase 1 Dose Escalation Study (NCT01222624) | Glycotope GmbH | 2009-11-01 |
| Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors (NCT01415297) | Niiki Pharma Inc. | 2009-10-01 |
| A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors (NCT00921869) | Eisai Co., Ltd. | 2009-10-01 |
| Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer (NCT00982566) | AbbVie | 2009-10-01 |
| A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects (NCT01009073) | AbbVie (prior sponsor, Abbott) | 2009-10-01 |
| A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer (NCT00878449) | AbbVie (prior sponsor, Abbott) | 2009-10-01 |
| Study of Cabozantinib (XL184) in Adults With Advanced Malignancies (NCT00940225) | Exelixis | 2009-09-01 |
| The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors (NCT00984425) | Istituto Clinico Humanitas | 2009-09-01 |